6% of patients in the 12-week telaprevir-based arm, the 8-week telaprevir-based
arm and the control
arm, respectively. Discontinuation of all
treatment due to
rash was 1.4%, 0.5% and 0.0% in the 12-week telaprevir-based arm, the 8-week telaprevir-based arm and the control arm, respectively, while discontinuation due to anemia was 0.8%, 3.3% and 0.6% in the 12-week telaprevir-based arm, the 8-week telaprevir-based arm and the control arm, respectively.